Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.
Phillips AN, Venter F, Havlir D, Pozniak A, Kuritzkes D, Wensing A, Lundgren JD, De Luca A, Pillay D, Mellors J, Cambiano V, Bansi-Matharu L, Nakagawa F, Kalua T, Jahn A, Apollo T, Mugurungi O, Clayden P, Gupta RK, Barnabas R, Revill P, Cohn J, Bertagnolio S, Calmy A. Phillips AN, et al. Among authors: venter f. Lancet HIV. 2019 Feb;6(2):e116-e127. doi: 10.1016/S2352-3018(18)30317-5. Epub 2018 Nov 29. Lancet HIV. 2019. PMID: 30503325 Free PMC article.
The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will.
Beyrer C, Birx DL, Bekker LG, Barré-Sinoussi F, Cahn P, Dybul MR, Eholié SP, Kavanagh MM, Katabira ET, Lundgren JD, Mworeko L, Pala M, Puttanakit T, Ryan O, Sidibé M, Montaner JS; Vancouver Consensus Signatories. Beyrer C, et al. Lancet. 2015 Aug 8;386(9993):505-7. doi: 10.1016/S0140-6736(15)61458-1. Lancet. 2015. PMID: 26293427 No abstract available.
HIV and risk of cardiovascular disease in sub-Saharan Africa: Rationale and design of the Ndlovu Cohort Study.
Vos A, Tempelman H, Devillé W, Barth R, Wensing A, Kretzschmar M, Klipstein-Grobusch K, Hoepelman A, Tesselaar K, Aitken S, Madzivhandila M, Uiterwaal C, Venter F, Coutinho R, Grobbee DE. Vos A, et al. Among authors: venter f. Eur J Prev Cardiol. 2017 Jul;24(10):1043-1050. doi: 10.1177/2047487317702039. Epub 2017 Apr 5. Eur J Prev Cardiol. 2017. PMID: 28379043 Free article.
The triumph of HIV treatment: another new antiretroviral.
Boffito M, Venter F. Boffito M, et al. Among authors: venter f. Lancet. 2017 Nov 4;390(10107):2019-2021. doi: 10.1016/S0140-6736(17)32297-3. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867498 No abstract available.
Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list.
Penazzato M, Townsend CL, Rakhmanina N, Cheng Y, Archary M, Cressey TR, Kim MH, Musiime V, Turkova A, Ruel TD, Rabie H, Sugandhi N, Rojo P, Doherty M, Abrams EJ; PADO4 participants. Penazzato M, et al. Lancet HIV. 2019 Sep;6(9):e623-e631. doi: 10.1016/S2352-3018(19)30193-6. Lancet HIV. 2019. PMID: 31498110 Review.
Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN, Bansi-Matharu L, Venter F, Havlir D, Pozniak A, Kuritzkes DR, Wensing A, Lundgren JD, Pillay D, Mellors J, Cambiano V, Jahn A, Apollo T, Mugurungi O, Ripin D, Da Silva J, Raizes E, Ford N, Siberry GK, Gupta RK, Barnabas R, Revill P, Cohn J, Calmy A, Bertagnolio S. Phillips AN, et al. Among authors: venter f. Lancet HIV. 2020 Mar;7(3):e193-e200. doi: 10.1016/S2352-3018(19)30400-X. Epub 2020 Feb 5. Lancet HIV. 2020. PMID: 32035041 Free PMC article.
150 results